$11.23
Live
Insights on Sotera Health Co
Revenue is up for the last 4 quarters, 220.59M → 310.23M (in $), with an average increase of 10.6% per quarter
Netprofit is up for the last 2 quarters, -13.66M → 38.68M (in $), with an average increase of 135.3% per quarter
In the last 1 year, Iqvia Holdings Inc. has given 25.6% return, outperforming this stock by 57.0%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 3.7% return, outperforming this stock by 59.9%
1.96%
Downside
Day's Volatility :5.17%
Upside
3.27%
4.63%
Downside
52 Weeks Volatility :44.79%
Upside
42.11%
Period | Sotera Health Co | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -24.51% | 1.7% | 0.0% |
6 Months | -11.26% | 11.3% | 0.0% |
1 Year | -31.36% | 5.4% | 1.3% |
3 Years | -57.0% | 13.9% | -22.1% |
Market Capitalization | 3.2B |
Book Value | $1.57 |
Earnings Per Share (EPS) | 0.18 |
PE Ratio | 63.22 |
PEG Ratio | 1.31 |
Wall Street Target Price | 16.9 |
Profit Margin | 4.9% |
Operating Margin TTM | 46.23% |
Return On Assets TTM | 7.08% |
Return On Equity TTM | 12.94% |
Revenue TTM | 1.0B |
Revenue Per Share TTM | 3.73 |
Quarterly Revenue Growth YOY | 23.3% |
Gross Profit TTM | 557.0M |
EBITDA | 514.1M |
Diluted Eps TTM | 0.18 |
Quarterly Earnings Growth YOY | -0.26 |
EPS Estimate Current Year | 0.71 |
EPS Estimate Next Year | 0.85 |
EPS Estimate Current Quarter | 0.26 |
EPS Estimate Next Quarter | 0.19 |
What analysts predicted
Upside of 50.49%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 746.1M | - |
Net Income | -5.9M | - |
Net Profit Margin | -0.79% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 778.3M | ↑ 4.31% |
Net Income | -20.4M | ↑ 247.96% |
Net Profit Margin | -2.62% | ↓ 1.83% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 818.2M | ↑ 5.12% |
Net Income | -37.5M | ↑ 83.55% |
Net Profit Margin | -4.58% | ↓ 1.96% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 931.5M | ↑ 13.85% |
Net Income | 116.9M | ↓ 411.76% |
Net Profit Margin | 12.55% | ↑ 17.13% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↑ 7.75% |
Net Income | -233.6M | ↓ 299.83% |
Net Profit Margin | -23.27% | ↓ 35.82% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↑ 4.54% |
Net Income | 51.4M | ↓ 122.0% |
Net Profit Margin | 4.9% | ↑ 28.17% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 248.7M | ↓ 6.73% |
Net Income | 25.1M | ↓ 17.52% |
Net Profit Margin | 10.09% | ↓ 1.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 251.6M | ↑ 1.16% |
Net Income | -319.7M | ↓ 1374.29% |
Net Profit Margin | -127.08% | ↓ 137.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 220.6M | ↓ 12.32% |
Net Income | 2.8M | ↓ 100.89% |
Net Profit Margin | 1.29% | ↑ 128.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 255.3M | ↑ 15.73% |
Net Income | 23.5M | ↑ 727.34% |
Net Profit Margin | 9.21% | ↑ 7.92% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 263.2M | ↑ 3.09% |
Net Income | -13.7M | ↓ 158.1% |
Net Profit Margin | -5.19% | ↓ 14.4% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 310.2M | ↑ 17.88% |
Net Income | 38.7M | ↓ 383.17% |
Net Profit Margin | 12.47% | ↑ 17.66% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.7B | - |
Total Liabilities | 2.7B | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | ↓ 4.72% |
Total Liabilities | 3.2B | ↑ 20.98% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.8B | ↑ 7.0% |
Total Liabilities | 2.3B | ↓ 28.4% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.8B | ↑ 1.02% |
Total Liabilities | 2.2B | ↓ 4.48% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.1B | ↑ 11.77% |
Total Liabilities | 2.8B | ↑ 25.6% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.1B | ↑ 0.41% |
Total Liabilities | 2.7B | ↓ 2.92% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.8B | ↓ 1.02% |
Total Liabilities | 2.2B | ↑ 0.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↑ 10.93% |
Total Liabilities | 2.8B | ↑ 25.57% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.4B | ↑ 9.51% |
Total Liabilities | 3.1B | ↑ 10.32% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 9.94% |
Total Liabilities | 2.7B | ↓ 12.99% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.0B | ↓ 1.25% |
Total Liabilities | 2.7B | ↑ 0.1% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↑ 3.09% |
Total Liabilities | 2.7B | ↑ 1.04% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 119.6M | ↑ 557.41% |
Investing Cash Flow | 96.6M | ↓ 1842.49% |
Financing Cash Flow | -191.9M | ↑ 7338.41% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 149.0M | ↑ 24.65% |
Investing Cash Flow | -57.3M | ↓ 159.25% |
Financing Cash Flow | -126.0M | ↓ 34.31% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 120.6M | ↓ 19.09% |
Investing Cash Flow | -158.7M | ↑ 177.16% |
Financing Cash Flow | 73.4M | ↓ 158.27% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 281.5M | ↑ 133.48% |
Investing Cash Flow | -159.8M | ↑ 0.72% |
Financing Cash Flow | -117.3M | ↓ 259.72% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 278.0M | ↓ 1.27% |
Investing Cash Flow | -181.9M | ↑ 13.8% |
Financing Cash Flow | 197.8M | ↓ 268.61% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 67.8M | ↑ 16.28% |
Investing Cash Flow | -39.0M | ↑ 9.12% |
Financing Cash Flow | -400.0K | ↓ 36.91% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 101.9M | ↑ 50.38% |
Investing Cash Flow | -71.7M | ↑ 84.1% |
Financing Cash Flow | 199.2M | ↓ 49911.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 33.9M | ↓ 66.77% |
Investing Cash Flow | -45.0M | ↓ 37.32% |
Financing Cash Flow | 273.9M | ↑ 37.48% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -336.6M | ↓ 1093.7% |
Investing Cash Flow | -53.1M | ↑ 18.16% |
Financing Cash Flow | -710.0K | ↓ 100.26% |
Sell
Neutral
Buy
Sotera Health Co is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Sotera Health Co | -4.09% | -11.26% | -31.36% | -57.0% | -55.1% |
Idexx Laboratories, Inc. | -6.69% | 19.77% | 2.28% | -11.49% | 117.09% |
Agilent Technologies Inc. | -5.54% | 32.97% | 5.46% | 0.11% | 79.21% |
Thermo Fisher Scientific, Inc. | 0.67% | 33.29% | 5.29% | 16.87% | 114.21% |
Danaher Corp. | 1.05% | 29.98% | 7.94% | -2.98% | 92.05% |
Iqvia Holdings Inc. | -3.23% | 32.9% | 25.63% | 3.18% | 75.33% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Sotera Health Co | 63.22 | 63.22 | 1.31 | 0.71 | 0.13 | 0.07 | NA | 1.57 |
Idexx Laboratories, Inc. | 49.04 | 49.04 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 33.3 | 33.3 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 37.17 | 37.17 | 2.81 | 21.53 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 46.53 | 46.53 | 3.13 | 7.15 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 32.69 | 32.69 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Sotera Health Co | Buy | $3.2B | -55.1% | 63.22 | 4.9% |
Idexx Laboratories, Inc. | Buy | $41.0B | 117.09% | 49.04 | 23.08% |
Agilent Technologies Inc. | Buy | $40.8B | 79.21% | 33.3 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $219.3B | 114.21% | 37.17 | 13.99% |
Danaher Corp. | Buy | $187.5B | 92.05% | 46.53 | 18.55% |
Iqvia Holdings Inc. | Buy | $43.4B | 75.33% | 32.69 | 9.06% |
Warburg Pincus LLC
GTCR LLC
HHG PLC
Vanguard Group Inc
BlackRock Inc
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
sotera health company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the united states and internationally. its sterilization services include gamma and electron beam irradiation, and eo processing; and lab services comprise analytical chemistry, medical device, and pharmaceutical lab testing, as well as microbiology testing. the company also provides co-60 and gamma irradiators, which are principal components to the gamma sterilization process. its microbiology testing services help customers to identify and measure the potential risks of microbes to a product and ensure that the quality of the products is maintained; and advisory services help customers in navigating the regulatory requirements applicable throughout the product lifecycle. the company was formerly known as sotera health topco, inc. and changed its name to sotera health company in october 2020. sotera health company was incorporated i
Organization | Sotera Health Co |
Employees | 3000 |
CEO | Mr. Michael B. Petras Jr. |
Industry | Commercial Services |
Cerevel Therapeutics Holdings Inc
$11.23
-0.35%
Vaxcyte Inc
$11.23
-0.35%
Janux Therapeutics Inc
$11.23
-0.35%
Spdr Nuveen S&p High Yield Municipal Bond Etf
$11.23
-0.35%
Radnet Inc
$11.23
-0.35%
The St. Joe Co
$11.23
-0.35%
Harley-davidson, Inc.
$11.23
-0.35%
Vaneck Vectors Fallen Angel Hiyld Bd Etf
$11.23
-0.35%
Aurora Innovation Inc
$11.23
-0.35%